{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:05Z","timestamp":1790727065169,"version":"4.1.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by rapidly progressive painful ulcers, and increasing evidence supports a role for the interleukin-36 pathway in its pathogenesis. We report the case of a 59-year-old woman with idiopathic refractory PG that evolved over 8\u2005years. The patient had an insufficient response to prolonged systemic corticosteroids and azathioprine, with persistent steroid dependency. Spesolimab was initiated as a single 900-mg intravenous infusion in combination with low-dose prednisone (10\u2005mg daily). This led to pain reduction, re-epithelialization and progressive ulcer healing, estimated at 30% after 3\u2005months, 50% after 6\u2005months and 80% after 8\u2005months. No major adverse events were observed, apart from an erysipelas-like reaction around the ulcers 3\u2005months later. Our review of published cases suggests that spesolimab may induce rapid and sustained improvement in refractory PG, although responses appear more heterogeneous in patients with underlying myeloid disorders. Overall, spesolimab appears to be a promising and well-tolerated therapeutic option for refractory PG, but further controlled studies are needed to better define its efficacy and safety, and place in the treatment algorithm.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag106","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:39:05Z","timestamp":1783532345000},"page":"816-820","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of spesolimab in resistant pyoderma gangrenosum: a case report and brief review of the literature"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4032-8155","authenticated-orcid":false,"given":"Kmar","family":"Turki","sequence":"first","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emna","family":"Bahloul","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Ennouri","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Chaabouni","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Boudaya","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Hammami","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Sellami","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slaheddine","family":"Marrakchi","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Bougacha","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamida","family":"Turki","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hedi Chaker University Hospital , Sfax ,","place":["Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026092919521083200_vzag106-B1","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3390\/ijms25042440","article-title":"The pathophysiology and treatment of pyoderma gangrenosum \u2013 current options and new perspectives","volume":"25","author":"\u0141yko","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026092919521083200_vzag106-B2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jid.2023.11.004","article-title":"Emerging role of the IL-36\/IL-36R axis in multiple inflammatory skin diseases","volume":"144","author":"Ahmad","year":"2024","journal-title":"J Invest Dermatol"},{"key":"2026092919521083200_vzag106-B3","doi-asserted-by":"crossref","first-page":"2460582","DOI":"10.1080\/09546634.2025.2460582","article-title":"Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases","volume":"36","author":"Zhang","year":"2025","journal-title":"J Dermatol Treat"},{"key":"2026092919521083200_vzag106-B4","doi-asserted-by":"crossref","first-page":"1581996","DOI":"10.3389\/fimmu.2025.1581996","article-title":"Case report: spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy","volume":"16","author":"Xin","year":"2025","journal-title":"Front Immunol"},{"key":"2026092919521083200_vzag106-B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2023.01.022","article-title":"Spesolimab use in treatment of pyoderma gangrenosum","volume":"34","author":"Gu\u00e9nin","year":"2023","journal-title":"JAAD Case Rep"},{"key":"2026092919521083200_vzag106-B6","doi-asserted-by":"crossref","first-page":"2451811","DOI":"10.1080\/09546634.2025.2451811","article-title":"Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline","volume":"36","author":"Zhang","year":"2025","journal-title":"J Dermatol Treat"},{"key":"2026092919521083200_vzag106-B7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaad.2025.08.084","article-title":"Heterogeneous response to spesolimab in pyoderma gangrenosum depends on underlying myeloid disorders","volume":"94","author":"Wang","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026092919521083200_vzag106-B8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ced\/llad317","article-title":"Rapid response to spesolimab in a patient with severe refractory pyoderma gangrenosum","volume":"49","author":"Ma","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2026092919521083200_vzag106-B9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/exd.14824","article-title":"Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study","volume":"32","author":"Burden","year":"2023","journal-title":"Exp Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/816\/68721679\/vzag106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/816\/68721679\/vzag106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:52:20Z","timestamp":1790725940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/5\/816\/8728486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":9,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag106","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,8]]}}}